DOMM has organized an expert lecture on 2nd January, 2021. The speaker, Ms. Rashmi Pant, is a leader in the market research consulting space. With over 22 years of experience and associations with Torrent Pharma, Intas Pharma, Sun Pharma Advanced Research Company, Veeda Clinical Research, and Cliantha Research, she has accumulated deep marketing intelligence based …

Continue reading “DOMM has organized an expert lecture on 2nd January, 2021”

Rashmi Participated in Pharmaconfex 2020 6th National conference on Pharma & Allied Sectors. Her session was focused on Basic Controls during Covid-19 in Pharma Industry

The Indian Clinical Trial market is currently going through challenging times. However Clinical Trial market ‘s major Growth Driver s are the patient trials on Off patent generic drugs i.e BA BE Studies. As far the sites for BA BE studies for Off patent drugs are concerned, the clinical trial sites for the same are reaching de growth …

Continue reading “Indian Clinical Trial Market Snapshot: Molecules, Health Conditions and Sites (2018-2019)”

Part 2. The post comes as a part of the series on the growing requirements of HCQ world wide. Global clinical trials are on for this very age old drug to collect additional and supporting evidence for treatment for COVID -19 virus. Simultaneously , there is a dire need to ramp up production of the …

Continue reading “The dilemma of HCQ production continues… Part 2”

This post comes as a part of the series of developments which are influencing the HCQ clinical trial market. Aggressive efforts of the developed and developing countries which are focused on new drug and vaccine research focused Clinical trials for Corona virus. Nearly 1000 multi centric trials for corona virus are currently in progress as …

Continue reading “Emerging clinical trials in COVID-19”

Will Indian pharma be able to overcome the challenges it faces in the COVID -19 crisis? Indian pharma which has less than 20 players in the HCQ formulation ( tablet ) market which is working day and night to enhance supplies of HCQ tablets for its Corona virus patients in India. Interestingly, HCQ is no …

Continue reading “The dilemma of HCQ production”

Rashmi Pant participated in the conference in Session 4 and Session 5 on the 15 Sep 2018 in the following roles: Panelist in the discussion titled – Quality Standardisation & Challenges for session 4 Panelist, speaker and Co Chairman in the session titled Nanotechnology, Nanomedicine and Biomedical Applications – Emerging Trends for session 5